Search
Ustekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalactive psoriatic arthritis, alone or in combination with [methotrexate]. … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.
Categories: Biologics for psoriasis treatmentProducts: Stelara Solution for Injection in Pre-Filled Syringe 90 mg/1 mL, STELARA 90MG/1ML SOLUTION FOR INJECTION IN PREFILLED SYRINGEPentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226415, L30300] Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated for … [A226410, A226415, A226455] More recently, PTX has been suggested as a possible treatment for COVID-19-induced pulmonary complications due to its ability to regulate the production of inflammatory cytokines
Categories: Compounds used in a research, industrial, or household setting, Drugs for Obstructive Airway DiseasesInternational brands: Ao Le Ni, An Ruo NingAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. … [A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: TECENTRIQ CONCENTRATE FOR SOLUTION FOR INFUSION 840MG/14ML, Tecentriq 60mg/ml Concentrate for Solution for InfusionBebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnBebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. … [L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use
Categories: Approved Treatments for COVID-19Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalbecome aggressive or black out. … In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine DependenceDoxecitine
go.drugbank.com/drugs/DB02594ApprovedInvestigationalIt is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair. … Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine.
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigational[L12771] It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate … has a higher affinity towards CD20.
Products: KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML, Bonspri 20mg/0.4mL Solution for Injection in Pre-filled syringeDimethicone 410
go.drugbank.com/drugs/DB14005Approved[L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%. … Dimethicone is a silicone-based polymer used as a moisturizer in different skin OTC products.[A32462] It is formed by repeated polymeric units of -(CH3)2SiO- with a terminal trimethyl siloxy unit.
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337ApprovedBNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19. … [L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.
Synonyms: BNT162B2 Omicron (LP.8.1)Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK … It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Categories: Experimental Unapproved Treatments for COVID-19